<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364022</url>
  </required_header>
  <id_info>
    <org_study_id>CCER 2020-00864</org_study_id>
    <nct_id>NCT04364022</nct_id>
  </id_info>
  <brief_title>Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland</brief_title>
  <acronym>COPEP</acronym>
  <official_title>Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calmy Alexandra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess, in a two-arm open-label cluster randomized clinical trial, the efficacy of
      a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed
      to a SARS-CoV-2 documented index patient, compared to surveillance alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).</measure>
    <time_frame>21-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)</measure>
    <time_frame>21-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)</measure>
    <time_frame>21-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of clinical COVID-19 on a 7-point ordinal scale</measure>
    <time_frame>21-day</time_frame>
    <description>(1: not hospitalized, no limitations on activities, 2: not hospitalized, limitation on activities, 3: hospitalized, not requiring supplemental oxygen, 4: hospitalized, requiring supplemental oxygen, 5: hospitalized, on non- invasive mechanical ventilation 6: hospitalized, on invasive mechanical ventilation or ECMO and 7: death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prevention of COVID-19</condition>
  <arm_group>
    <arm_group_label>Lopinavir/Ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>2x 200mg/50mg, twice daily for 5 days (bid, PO)</description>
    <arm_group_label>Lopinavir/Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Documented close contact with a PCR-confirmed SARS-CoV-2 positive individual

          2. ≥ 16 years of age;

          3. Informed consent as documented by signature (including parent's or legal guardian's
             signature if the participant is 16 and 18 y.o.);

        Exclusion criteria*:

          1. Fever (temperature &gt;38.0°) and/or respiratory symptoms (cough, dyspnoea) and/or new
             anosmia/ageusia;

          2. Individuals with previous confirmed SARS-CoV-2 infection, dating within the last six
             months ;

          3. Known impairment of liver function;

          4. Known hypersensitivity to the study medications;

          5. Use of any medications that are contraindicated with lopinavir/ritonavir using the
             website www.hiv-druginteractions.org/checker

          6. Individuals on boosted protease inhibitor (other than LPV) or boosted elvitegravir as
             part of an antiretroviral therapy

          7. Inability to be followed-up for the trial period

               -  Where necessary, additional biological and clinical assessment will be performed,
                  based on clinical judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Calmy, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Genève</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niklaus Labhardt, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Calmy, Prof</last_name>
    <phone>223729811</phone>
    <phone_ext>41</phone_ext>
    <email>alexandra.calmy@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsspital Basel and SwissTPH</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Calmy, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra Calmy, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Calmy Alexandra</investigator_full_name>
    <investigator_title>Prof. Alexandra Calmy</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

